GeoVax Strengthens Patent Portfolio for Innovative Cancer Treatment Approach
TL;DR
GeoVax Labs, Inc. strengthens its intellectual property position in oncology with patented triple-combination therapy for solid tumors.
Method involves intratumoral administration of Ad/PNP adenoviral vector, prodrug F-araAMP, and radiation therapy for targeted cytotoxic activity in tumor microenvironment.
GeoVax's patented therapy offers promise in expanding therapeutic options for difficult-to-treat cancers, minimizing systemic toxicity, and improving patient outcomes.
Gedeptin, a viral-vectored gene therapy, selectively kills tumor cells with reduced side effects and potential immune checkpoint inhibitor synergy across multiple solid tumor types.
Found this article helpful?
Share it with your network and spread the knowledge!
Biotechnology company GeoVax Labs has expanded its intellectual property protection for Gedeptin®, a promising cancer therapy platform, through a newly allowed U.S. patent covering an innovative treatment approach for solid tumors.
The patent describes a unique therapeutic method involving three key steps: direct intratumoral administration of an adenoviral vector, local prodrug administration, and targeted radiation therapy. This strategy aims to generate localized cytotoxic activity within tumor microenvironments while minimizing systemic side effects.
The newly protected approach could potentially treat multiple cancer types, including glioblastoma, breast, prostate, head and neck, glioma, and lung cancers. By focusing on targeted delivery, the method represents a significant advancement in precision oncology.
GeoVax's intellectual property portfolio now encompasses over 135 granted or pending patent applications across 23 distinct patent families. The company has exclusively licensed the Gedeptin platform through an agreement with PNP Therapeutics, Inc. and the University of Alabama at Birmingham.
This patent expansion comes as GeoVax prepares to initiate a Phase 2 clinical trial combining Gedeptin with an Immune Checkpoint Inhibitor for patients with first recurrence of head and neck cancer. The new patent claims provide additional protection as the company explores potential partnerships and expanded therapeutic applications.
The innovative approach leverages a non-replicating adenoviral vector encoding a bacterial enzyme that converts a prodrug into a cytotoxic metabolite, offering a potentially more precise cancer treatment mechanism. This method could represent a significant step forward in developing less invasive and more targeted cancer therapies.
Curated from NewMediaWire
